
Brian Gill Barnett MD
Breast Cancer, Hematologic Oncology
Medical Director/Genentech
Join to view full profile
17050 Medical Center DrBaton Rouge, LA 70816
Phone+1 225-755-3070
Fax+1 225-755-3085
Dr. Barnett is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Stanford Health Care-Sponsored Stanford UniversityResidency, Gastroenterology, 2016 - 2022
Tulane UniversityFellowship, Hematology and Medical Oncology, 2004 - 2006
Tulane UniversityResidency, Internal Medicine, 2002 - 2004
University of Mississippi Medical CenterInternship, Internal Medicine, 1998 - 1999
University of Mississippi School of MedicineClass of 1998
Certifications & Licensure
LA State Medical License 2002 - 2027
Publications & Presentations
PubMed
- 20 citationsDelay in initiation of adjuvant trastuzumab therapy leads to decreased overall survival and relapse-free survival in patients with HER2-positive non-metastatic breast ...Christopher Gallagher, Kenneth More, Tripthi Kamath, Anthony Masaquel, Annie Guerin
Breast Cancer Research and Treatment. 2016-04-23 - 31 citationsHuman leukocyte antigen G expression in breast cancer: role in immunosuppression.Robert L. Elliott, Xian P. Jiang, Jeffrey T. Phillips, Brian G. Barnett, Jonathan F. Head
Cancer Biotherapy & Radiopharmaceuticals. 2011-05-03 - 51 citationsAltering regulatory T cell function in cancer immunotherapy: a novel means to boost the efficacy of cancer vaccines.Jens Rüter, Brian G. Barnett, Ilona Kryczek, Michael J. Brumlik, Benjamin J. Daniel
Frontiers in Bioscience. 2009-01-01
Press Mentions
Merck Dives Into Detailed Phase 3 Data Showing PCSK9 Pill Easily Outswims RivalsMarch 30th, 2026
Cleveland Clinic Enters into Collaboration to Acquire Psilocybin, DMT and MDMA for Clinical InvestigationApril 20th, 2020
OncBioMune Pharmaceuticals, Inc. (OTCMKTS:OBMP) Files an 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersMarch 19th, 2019
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:









